From the helm: Amplia Therapeutics (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim.

Bell Direct
March 20, 2026

In this episode of From the Helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US.

Key Benefits of an SMSF

Bell Direct
April 2, 2020

The Bell Direct SMSF Service

Bell Direct
April 2, 2020

Morning Bell 2 April

Jessica Amir
April 2, 2020

Market Update 1 April

Jessica Amir
April 1, 2020

March Market Overview

Jessica Amir
March 31, 2020

Morning Bell 25 March

Jessica Amir
March 25, 2020

Weekly Wrap 20 March

Bell Direct
March 20, 2020

Market Update 20 March

Jessica Amir
March 20, 2020

Market Update 19 March

Jessica Amir
March 19, 2020

Morning Bell 18 March

Jessica Amir
March 18, 2020

Morning Bell 17 March

Jessica Amir
March 17, 2020